Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).

Pharmaceutical research - 1 Jul 2008

Gonzalez-Covarrubias Vanessa, Kalabus James L, Blanco Javier G

Abstract excerpt

PURPOSE: Carbonyl reductase 1 (CBR1) reduces the anticancer anthracyclines doxorubicin and daunorubicin into the cardiotoxic metabolites doxorubicinol and daunorubicinol. We evaluated whether the cardioprotectant monoHER inhibits the activity of polymorphic CBR1. METHODS: We performed enzyme kinetic studies with monoHER, CBR1 (CBR1 V88 and CBR1 I88) and anthracycline substrates. We also characterized CBR1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases
Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cardiotonic Agents

Share to Data Interpretation, Statistical

Share to Daunorubicin

Share to Doxorubicin

Share to Enzyme Inhibitors

Share to Recombinant Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 18449627
DOI: 10.1007/s11095-008-9592-5
PMCID: PMC2897163

Genes

CBR1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).PMID 18449627Read ↗

A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.Semantic proximity Read ↗

Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.Semantic proximity Read ↗

Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.Semantic proximity Read ↗

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.Semantic proximity Read ↗

Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.Semantic proximity Read ↗

Risk factors for anthracycline-associated cardiotoxicity.Semantic proximity Read ↗

Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.Semantic proximity Read ↗

Human carbonyl reductase 1 participating in intestinal first-pass drug metabolism is inhibited by fatty acids and acyl-CoAs.Semantic proximity Read ↗

Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2.Semantic proximity Read ↗

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.Semantic proximity Read ↗

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.Semantic proximity Read ↗

Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.